Multiple Myeloma

Shaji Kumar, MD, professor of Medicine, Mayo Clinic, discusses some of the recent advancements, including FDA approvals, in the field of multiple myeloma.

A novel target, B-cell maturation antigen, has been identified for future therapeutic development as chimeric antigen receptor T-cell therapy for patients with multiple myeloma.

Saad Z. Usmani, MD, Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute/Carolinas HealthCare System, discusses combining daratumumab (Darzalex) for patients with multiple myeloma.

Consolidation therapy with lenalidomide, bortezomib, and dexamethasone (RVD), when used in conjunction with stem cell transplantation, extended progression-free survival compared with RVD alone in patients with multiple myeloma.

There is no comprehensive, multidisciplinary guideline document for the screening, management, and long-term care of myeloma patients. The UK Myeloma Forum and the British Society for Haematology set out to address this need and published such a guideline in a recent issue of the British Journal of Hematology.

Michael A. Thompson, MD, PhD, medical director, precision medicine, Vince Lombardi Cancer Clinic, Aurora Health Care, discusses challenges facing the field of multiple myeloma.

The past several decades have witnessed a dramatic improvement in the treatment of patients with multiple myeloma, the second most common type of hematologic malignancy. A better understanding of the biology of this disease and the introduction of a wealth of novel drug classes has more than doubled median survival times.

A supplemental biologics license application has been submitted to the FDA for the use of denosumab for the prevention of skeletal-related events in patients with multiple myeloma.

C. Ola Landgren, MD, PhD, chief of Myeloma Service at Memorial Sloan Kettering Cancer Center, discusses managing toxicities associated with multiple myeloma treatment.

Eric Smith, MD, PhD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses chimeric androgen receptor (CAR) T-cell therapy in multiple myeloma.

Sundar Jagannath, MD, director of the Multiple Myeloma program and professor of medicine at the Tisch Cancer Institute, Mount Sinai Cancer Center, discusses the potential impact of immunotherapy in multiple myeloma.

Graham Jackson, MD, PhD, Northern Institute for Cancer Research, Newcastle University, discusses some of the ongoing challenges in the treatment of patients with multiple myeloma.

Saad Z. Usmani, MD, Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute/Carolinas HealthCare System, discusses the mechanisms of daratumumab (Darzalex) as well as the reported response rates in combination with other agents in multiple myeloma.

Michael A. Thompson, MD, PhD, medical director, precision medicine, Vince Lombardi Cancer Clinic, Aurora Health Care, discusses the future of treatment in multiple myeloma.

C. Ola Landgren, MD, PhD, chief of Myeloma Service at Memorial Sloan Kettering Cancer Center, discusses using daratumumab (Darzalex) for the treatment of patients with multiple myeloma.

Sagar Lonial, MD, professor and chair, Department of Hematology & Medical Oncology, Emory University School of Medicine, chief medical officer, Winship Cancer Institute of Emory University, discusses updates in multiple myeloma.

Sagar Lonial, MD, discusses recent advances that have revolutionized the treatment of patients with multiple myeloma.